Zobrazeno 1 - 10
of 44
pro vyhledávání: '"Stephen J. Greene"'
Autor:
Josephine Harrington, Gregg C. Fonarow, Muhammad Shahzeb Khan, Adrian Hernandez, Stefan Anker, Michael Böhm, Stephen J. Greene, G. Michael Felker, Muthiah Vaduganathan, Javed Butler
Publikováno v:
JACC Heart Fail
BACKGROUND: Initiation and up-titration of guideline-directed medical therapies (GDMT) for heart failure with reduced ejection fraction (HFrEF) remains suboptimal, in part due to concerns regarding tolerability and adverse events (AE). OBJECTIVES: To
Autor:
Stephen J. Greene, Evan M Murray, Muthiah Vaduganathan, Michael E. Nassif, Darren K. McGuire, Vishal N. Rao, Gregg C. Fonarow, JoAnn Lindenfeld, Kavita Sharma, Javed Butler, Robert J. Mentz, Neha J. Pagidipati, Zachary L. Cox, Lauren B. Cooper, Cara O'Brien, Mona Fiuzat, Jennifer B. Green, Orly Vardeny
Publikováno v:
J Am Coll Cardiol
Sodium-glucose cotransporter-2 inhibitor therapy is well suited for initiation during the heart failure hospitalization, owing to clinical benefits that accrue rapidly within days to weeks, a strong safety and tolerability profile, minimal to no effe
Autor:
Izza Shahid, Muhammad Shahzeb Khan, Tariq Jamal Siddiqi, Muhammad Sameer Arshad, Arisha Saleem, Harriette G.C. Van Spall, Nosheen Reza, Stephen J. Greene, Erin D. Michos
Publikováno v:
J Am Coll Cardiol
Autor:
Javed Butler, Stephen J. Greene, Robert J. Mentz, Jie-Lena Sun, Marco Metra, Adrian F. Hernandez, Adriaan A. Voors, Vanessa Blumer, Christopher M. O'Connor
Publikováno v:
Circulation: Heart Failure, 14(4), 431-441. LIPPINCOTT WILLIAMS & WILKINS
Circ Heart Fail
Circ Heart Fail
Background: Hospitalization for heart failure (HF) is associated with increased risk of death among patients with chronic HF. The degree to which hospitalization for HF is a distinct biologic entity with independent prognostic value versus a marker o
Autor:
Michel G, Khouri, Stephen J, Greene
Publikováno v:
JACC Heart Fail
BACKGROUND: Sodium-glucose co-transporter-2 (SGLT2) inhibitors improve outcomes among patients with established heart failure. Despite supportive basic science studies, there are no data on the value of SGLT2 inhibitors among patients treated with an
Autor:
Sardar Hassan Ijaz, Shakeel Jamal, Abdul Mannan Khan Minhas, Abu Baker Sheikh, Salik Nazir, Muhammad Shahzeb Khan, Anum S. Minhas, Allison G. Hays, Haider J. Warraich, Stephen J. Greene, Marat Fudim, Michael C. Honigberg, Sadiya S. Khan, Timir K. Paul, Erin D. Michos
Publikováno v:
Am J Cardiol
Data are limited on contemporary temporal trends in maternal characteristics and outcomes in hospitalized patients with peripartum cardiomyopathy (PC). We used the National Inpatient Sample database from January 1, 2004, to December 31, 2018, to iden
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c059d0d3560efcaf67cbd65ce15ec53b
https://europepmc.org/articles/PMC9944609/
https://europepmc.org/articles/PMC9944609/
Publikováno v:
Expert Rev Cardiovasc Ther
I. INTRODUCTION: Torsemide is a loop diuretic that inhibits the Na+/K+/2Cl− cotransporter type 2 in the thick ascending loop of Henle, leading to increased excretion of urinary sodium and chloride and associated diuresis. While furosemide remains t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c184e5349d9f4bf8c0f8f683badbf0e0
https://europepmc.org/articles/PMC8887994/
https://europepmc.org/articles/PMC8887994/
Autor:
Muthiah Vaduganathan, Marvin A. Konstam, Gregg C. Fonarow, Javed Butler, Stephen J. Greene, Faiez Zannad, Ravi B. Patel, Ankeet S. Bhatt, Haris Subacius
Publikováno v:
European Journal of Heart Failure
European Journal of Heart Failure, 2020, 22 (1), pp.164-167. ⟨10.1002/ejhf.1651⟩
Eur J Heart Fail
European Journal of Heart Failure, 2020, 22 (1), pp.164-167. ⟨10.1002/ejhf.1651⟩
Eur J Heart Fail
International audience
Autor:
Anju Nohria, Stephen J. Greene, Lynne W. Stevenson, Gregg C. Fonarow, Javed Butler, Muthiah Vaduganathan, Gaspare Parrinello, Pietro Di Pasquale, Mihai Gheorghiade, Michael H. Alderman, Luna Gargani, Joseph V. Bonventre, Daniele Torres, Salvatore Paterna
Publikováno v:
Heart failure reviewsReference. 26(6)
Despite all available therapies, the rates of hospitalization and death from heart failure (HF) remain unacceptably high. The most common reasons for hospital admission are symptoms related to congestion. During hospitalization, most patients respond
Autor:
John A. Spertus, Carol I. Duffy, Adam D. DeVore, Stephen J. Greene, Laine Thomas, Gregg C. Fonarow, Muthiah Vaduganathan, C. Larry Hill, Javed Butler, Nancy M. Albert
Publikováno v:
J Am Coll Cardiol
Patients with heart failure with reduced ejection fraction (HFrEF) face high risks of deterioration in health status, hospitalization, or death. Diabetes mellitus (DM) is a frequent comorbidity that adds therapeutic complexity and further contributes